Innovation Pharmaceuticals Inc. (IPIX)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -3.11 Million USD | 55.05% |
| 2022 | -6.92 Million USD | 23.23% |
| 2021 | -9.01 Million USD | -94.5% |
| 2020 | -4.63 Million USD | 28.15% |
| 2019 | -6.45 Million USD | 53.73% |
| 2018 | -13.94 Million USD | 9.08% |
| 2017 | -15.33 Million USD | -21.19% |
| 2016 | -12.65 Million USD | 2.33% |
| 2015 | -12.95 Million USD | -61.18% |
| 2014 | -8.03 Million USD | -169.46% |
| 2013 | -2.98 Million USD | 28.93% |
| 2012 | -4.19 Million USD | 27.29% |
| 2011 | -5.77 Million USD | -71.59% |
| 2010 | -3.36 Million USD | -131.85% |
| 2009 | -1.45 Million USD | -184.4% |
| 2008 | -510.19 Thousand USD | -981.81% |
| 2007 | -47.16 Thousand USD | -38.21% |
| 2006 | -34.12 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -223 Thousand USD | -28.87% |
| 2023 Q2 | -347 Thousand USD | 75.44% |
| 2023 Q1 | -1.41 Million USD | 0.91% |
| 2023 Q3 | -679 Thousand USD | -95.68% |
| 2023 Q4 | -672 Thousand USD | 1.03% |
| 2023 FY | -2.93 Million USD | 57.54% |
| 2022 Q1 | -2.02 Million USD | 20.01% |
| 2022 FY | -6.92 Million USD | 23.23% |
| 2022 Q4 | -1.42 Million USD | 2.19% |
| 2022 Q3 | -1.45 Million USD | 27.61% |
| 2022 Q2 | -2.01 Million USD | 0.44% |
| 2021 Q2 | -3.43 Million USD | -204.61% |
| 2021 Q3 | -1.91 Million USD | 44.23% |
| 2021 Q4 | -2.52 Million USD | -31.86% |
| 2021 FY | -9.01 Million USD | -94.5% |
| 2021 Q1 | -1.12 Million USD | 20.72% |
| 2020 FY | -4.63 Million USD | 28.15% |
| 2020 Q2 | -1.34 Million USD | -42.93% |
| 2020 Q1 | -941 Thousand USD | 29.25% |
| 2020 Q3 | -925 Thousand USD | 31.23% |
| 2020 Q4 | -1.42 Million USD | -53.95% |
| 2019 Q1 | -1.99 Million USD | 22.91% |
| 2019 Q3 | -1.12 Million USD | 43.43% |
| 2019 Q4 | -1.33 Million USD | -17.91% |
| 2019 FY | -6.45 Million USD | 53.73% |
| 2019 Q2 | -1.99 Million USD | 0.25% |
| 2018 Q2 | -4.46 Million USD | 0.36% |
| 2018 Q4 | -2.59 Million USD | -8.13% |
| 2018 FY | -13.94 Million USD | 9.08% |
| 2018 Q1 | -4.48 Million USD | 13.72% |
| 2018 Q3 | -2.39 Million USD | 46.33% |
| 2017 Q3 | -3.85 Million USD | -16.41% |
| 2017 FY | -15.33 Million USD | -21.19% |
| 2017 Q4 | -5.19 Million USD | -34.92% |
| 2017 Q2 | -3.3 Million USD | -11.11% |
| 2017 Q1 | -2.97 Million USD | 6.79% |
| 2016 Q2 | -3.27 Million USD | -29.56% |
| 2016 Q3 | -3.65 Million USD | -11.76% |
| 2016 Q1 | -2.52 Million USD | 17.2% |
| 2016 FY | -12.65 Million USD | 2.33% |
| 2016 Q4 | -3.19 Million USD | 12.68% |
| 2015 Q1 | -4.35 Million USD | -32.33% |
| 2015 Q3 | -2.84 Million USD | -5.21% |
| 2015 Q2 | -2.7 Million USD | 37.9% |
| 2015 FY | -12.95 Million USD | -61.18% |
| 2015 Q4 | -3.05 Million USD | -7.28% |
| 2014 Q4 | -3.29 Million USD | -44.13% |
| 2014 FY | -8.03 Million USD | -169.46% |
| 2014 Q3 | -2.28 Million USD | -47.64% |
| 2014 Q2 | -1.54 Million USD | -68.31% |
| 2014 Q1 | -918.65 Thousand USD | 15.3% |
| 2013 FY | -2.98 Million USD | 28.93% |
| 2013 Q1 | -408.91 Thousand USD | 72.99% |
| 2013 Q2 | -688.74 Thousand USD | -68.43% |
| 2013 Q3 | -800.75 Thousand USD | -16.26% |
| 2013 Q4 | -1.08 Million USD | -35.45% |
| 2012 Q4 | -1.51 Million USD | -111.42% |
| 2012 FY | -4.19 Million USD | 27.29% |
| 2012 Q2 | -1.07 Million USD | -19.97% |
| 2012 Q1 | -894.15 Thousand USD | 29.02% |
| 2012 Q3 | -716.15 Thousand USD | 33.24% |
| 2011 FY | -5.77 Million USD | -71.59% |
| 2011 Q3 | -2.22 Million USD | -72.53% |
| 2011 Q4 | -1.25 Million USD | 43.47% |
| 2011 Q1 | -992.62 Thousand USD | -13.63% |
| 2011 Q2 | -1.29 Million USD | -30.12% |
| 2010 FY | -3.36 Million USD | -131.85% |
| 2010 Q2 | -1.18 Million USD | -123.3% |
| 2010 Q4 | -873.53 Thousand USD | -11.77% |
| 2010 Q3 | -781.52 Thousand USD | 33.79% |
| 2010 Q1 | -528.6 Thousand USD | -71.12% |
| 2009 FY | -1.45 Million USD | -184.4% |
| 2009 Q4 | -308.9 Thousand USD | 51.87% |
| 2009 Q3 | -641.87 Thousand USD | -103.08% |
| 2009 Q2 | -316.06 Thousand USD | -71.66% |
| 2009 Q1 | -184.12 Thousand USD | 14.9% |
| 2008 Q1 | -15.57 Thousand USD | 3.92% |
| 2008 Q2 | -117.63 Thousand USD | -655.49% |
| 2008 FY | -510.19 Thousand USD | -981.81% |
| 2008 Q3 | -176.2 Thousand USD | -49.8% |
| 2008 Q4 | -216.35 Thousand USD | -22.78% |
| 2007 Q2 | -13.42 Thousand USD | -42.22% |
| 2007 Q3 | -9100.00 USD | 32.19% |
| 2007 Q1 | -9436.00 USD | 0.0% |
| 2007 Q4 | -16.2 Thousand USD | -78.08% |
| 2007 FY | -47.16 Thousand USD | -38.21% |
| 2006 FY | -34.12 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| HST Global, Inc. | -140.9 Thousand USD | -2107.839% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -352.871% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -1713.893% |
| CytoDyn Inc. | -18.05 Million USD | 82.772% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 94.726% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| MultiCell Technologies, Inc. | -722.81 USD | -430303.564% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -71.28% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 38.329% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -10286.619% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -1614.191% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Alpha Cognition Inc. | -9.7 Million USD | 67.946% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 94.395% |
| SQZ Biotechnologies Company | -75.82 Million USD | 95.897% |
| Resverlogix Corp. | -12.74 Million USD | 75.598% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -698.573% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 131.932% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -26.705% |
| Mesoblast Limited | -84.14 Million USD | 96.303% |
| GB Sciences, Inc. | -1.42 Million USD | -119.006% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -352.871% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 82.568% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 8.634% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 53.204% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 1.808% |
| ContraFect Corporation | -56.88 Million USD | 94.531% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -13.093% |
| BioStem Technologies, Inc. | -7.77 Million USD | 60.008% |
| LadRx Corporation | -3.82 Million USD | 18.637% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 80.397% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -178.016% |
| CSL Limited | 3.7 Billion USD | 100.084% |
| Biomind Labs Inc. | -1 Million USD | -208.141% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -234.02% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 103.801% |
| Nascent Biotech, Inc. | -2.22 Million USD | -39.514% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 95.666% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 163.298% |
| GeneThera, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 187.881% |
| Adynxx, Inc. | - USD | Infinity% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -102.533% |
| Marizyme, Inc. | -34.08 Million USD | 90.873% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 62.743% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -450.89% |
| Zenith Capital Corp. | -8.94 Million USD | 65.213% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -9.138% |
| Halberd Corporation | -75.05 Thousand USD | -4045.237% |
| Genus plc | 6.4 Million USD | 148.609% |
| Pharming Group N.V. | -4.87 Million USD | 36.244% |
| MetaStat, Inc. | - USD | Infinity% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -56.609% |
| IMV Inc. | -38.67 Million USD | 91.955% |
| Affymax, Inc. | -15.04 Million USD | 79.323% |
| SYBLEU INC | -149.18 Thousand USD | -1985.4% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -197.989% |
| Enzolytics Inc. | -2.14 Million USD | -44.778% |
| argenx SE | -425.04 Million USD | 99.268% |
| AVAX Technologies, Inc. | 6.69 Million USD | 146.482% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -121.899% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -132.958% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Accustem Sciences Inc. | -3.74 Million USD | 16.961% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -12259.952% |
| Cell Source, Inc. | -4.32 Million USD | 28.075% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -544.017% |
| Q BioMed Inc. | -3.44 Million USD | 9.711% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 26.6% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -147.691% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -18.401% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 31.697% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 94.341% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -7.23% |
| Rebus Holdings, Inc. | -664 Thousand USD | -368.524% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -216.142% |
| Skye Bioscience, Inc. | -13.67 Million USD | 77.245% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -66.866% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -55.181% |
| ONE Bio Corp. | 13.68 Million USD | 122.739% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -60.974% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -176.556% |
| Agentix Corp. | -1.37 Million USD | -126.79% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -6.561% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -96.979% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -17757.758% |
| Kadimastem Ltd | -3.04 Million USD | -2.327% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -1088.648% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -648.774% |
| NovAccess Global Inc. | -2.46 Million USD | -26.117% |
| Itoco Inc. | -919.14 Thousand USD | -238.469% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -1313.59% |
| Qrons Inc. | -643.67 Thousand USD | -383.317% |
| Mobile Lads Corp. | -554.55 Thousand USD | -460.995% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.252% |
| International Stem Cell Corporation | -663 Thousand USD | -369.231% |
| Bioxytran, Inc. | -3.82 Million USD | 18.563% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -5809.954% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -15194.985% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 91.422% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -92.274% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -322.785% |
| Neutra Corp. | -229.48 Thousand USD | -1255.638% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 82.262% |
| PureTech Health plc | -146.19 Million USD | 97.872% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 85.524% |
| IXICO plc | -1.43 Million USD | -116.493% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 67.222% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 97.446% |
| CSL Limited | 3.81 Billion USD | 100.082% |
| Cellectis S.A. | -108.85 Million USD | 97.142% |